Osteoarthritis: Two-Year Results Show Benefits of Orthokine Therapy
DÜSSELDORF, GERMANY, September 12, 2007-Within the scope of the German Osteoarthritis Trial (GOAT) the effects of different innovative medications in osteoarthritis (OA) therapy were studied. All 376 participants in the trial suffered from painful OA of the knee joint and were treated with Orthokine, hyaluronic acid, or placebo injections. Orthokine therapy uses autologous, anti-inflammatory proteins, which are isolated from the patient’s blood and injected into the joint. Six months after the treatment, the outcome differed depending on the therapy: The condition of Orthokine-treated patients was found to be much better than that of patients treated with hyaluronic acid or placebo. The trial was conducted by the Heinrich Heine University in collaboration with the Center for Molecular Orthopaedics (Düsseldorf, Germany) and was recently published in the scientific journal “Biodrugs.” In the meantime, results obtained over two years give further support to the therapy utilising autologous proteins.
In past years, scientists have set high hopes on so-called biologicals-therapies using biological substances. These should directly address the cause of the disease and as a result, be particularly effective. Following a long period of developing new approaches against OA-among others the Orthokine therapy-biologicals are in the clinical trial phase. During this phase, the GOAT study was a milestone in the clinical research of the use of biologicals in orthopaedics.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.